Related Experiment Video
Updated: Aug 13, 2026

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
Published on: February 16, 2022
Ultrasound-induced nitric oxide release from isosorbide dinitrate nanoparticles for on-demand therapy of
Xinchao Wang1, Zhilin Liu2, Fengli Wu1
1Hospital of Stomatology, Jilin University, Changchun, China.
Abstract:
Nitric oxide (NO) can effectively combat periodontitis by disrupting biofilms and suppressing inflammation; however, its clinical translation has been limited by the lack of a controllable delivery strategy. This study aimed to develop an ultrasound-controlled NO delivery platform based on a clinically approved NO donor for precise periodontitis treatment. A clinically approved NO donor, isosorbide dinitrate (ISDN), was identified that can be efficiently activated by low-intensity ultrasound (2 W/cm2) in the presence of vitamin B2 tetrabutyrate (TBR) by generating ·OH free radicals, thereby releasing NO in an on-demand and spatiotemporally controlled manner. Thereafter, ISDN-loaded nanoparticles were synthesized, and a miniaturized intraoral ultrasonic transducer for localized NO generation was developed. The reaction between NO and the reactive oxygen species (ROS) produced from TBR formed peroxynitrite, which exerted strong antibacterial and anti-biofilm effects (the bacterial survival rate within the biofilm during the formation stage was less than 10%) and inhibited NLRP3-mediated inflammation. In a rat model of periodontitis, the treatment significantly decreased bacterial load and mitigated inflammation, resulting in a reduction of inflammatory gene expression by approximately 2.4-fold, while maintaining the integrity of alveolar bone structure. Overall, this study presents a highly promising clinical application for ultrasound-controlled NO delivery strategy for precision therapy of periodontitis.
Related Concept Videos
Nitric Oxide Signaling Pathway
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Factors Affecting Dissolution: Particle Size and Effective Surface Area

